Apogee Therapeutics, Inc. Investment Income, Interest
Apogee Therapeutics, Inc. (APGE) reported Investment Income, Interest of $11.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-10
- Apogee Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $11.81M, a 65.35% increase year-over-year.
- Apogee Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $8.74M, a 11.48% increase year-over-year.
- Apogee Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $8.73M, a 0.58% increase year-over-year.
- Apogee Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $6.32M, a 34.65% decline year-over-year.
- Apogee Therapeutics, Inc. investment income, interest for fiscal 2025 was $30.03M, a 13.56% decline from fiscal 2024.
- Apogee Therapeutics, Inc. investment income, interest for fiscal 2024 was $34.74M, a 285.25% increase from fiscal 2023.
- Apogee Therapeutics, Inc. investment income, interest for fiscal 2023 was $9.02M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 11 month | Investment Income, Interest 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $11.81M 10-Q · filed 2026-08-10 | $20.55M 10-Q · filed 2026-08-10 | $29.28M derived: sum of 3 quarters · filed 2026-08-10 | $35.60M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2026-03-31 | $8.74M 10-Q · filed 2026-05-11 | $17.47M derived: sum of 2 quarters · filed 2026-05-11 | $23.79M derived: sum of 3 quarters · filed 2026-05-11 | $30.93M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-12-31 | $8.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $15.05M derived: sum of 2 quarters · filed 2026-03-02 | $22.19M derived: sum of 3 quarters · filed 2026-08-10 | $30.03M 10-K · filed 2026-03-02 | |
| 2025-09-30 | $6.32M 10-Q · filed 2025-11-10 | $13.46M derived: sum of 2 quarters · filed 2026-08-10 | $21.30M 10-Q · filed 2025-11-10 | $29.98M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-06-30 | $7.14M 10-Q · filed 2026-08-10 | $14.98M 10-Q · filed 2026-08-10 | $23.66M derived: sum of 3 quarters · filed 2026-08-10 | $33.33M derived: sum of 4 quarters · filed 2026-08-10 | |
| 2025-03-31 | $7.84M 10-Q · filed 2026-05-11 | $16.52M derived: sum of 2 quarters · filed 2026-05-11 | $26.19M derived: sum of 3 quarters · filed 2026-05-11 | $36.49M derived: sum of 4 quarters · filed 2026-05-11 | |
| 2024-12-31 | $8.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $18.35M derived: sum of 2 quarters · filed 2026-03-02 | $28.66M derived: sum of 3 quarters · filed 2026-03-02 | $34.74M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $9.67M 10-Q · filed 2025-11-10 | $19.97M derived: sum of 2 quarters · filed 2025-11-10 | $26.06M 10-Q · filed 2025-11-10 | $31.48M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-06-30 | $10.31M 10-Q · filed 2025-08-11 | $16.39M 10-Q · filed 2025-08-11 | $21.81M derived: sum of 3 quarters · filed 2026-03-02 | $25.28M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2024-03-31 | $6.09M 10-Q · filed 2025-05-12 | $11.51M derived: sum of 2 quarters · filed 2026-03-02 | $14.97M derived: sum of 3 quarters · filed 2026-03-02 | $14.97M derived: sum of 4 quarters · filed 2026-03-02 | |
| 2023-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.88M derived: sum of 2 quarters · filed 2026-03-02 | $8.88M derived: sum of 3 quarters · filed 2026-03-02 | $9.02M 10-K · filed 2026-03-02 | |
| 2023-09-30 | $3.46M 10-Q · filed 2024-11-12 | $3.46M derived: sum of 2 quarters · filed 2024-11-12 | $3.60M 10-Q · filed 2024-11-12 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $133.00K 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | $133.00K 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | $92.00K 10-K · filed 2024-03-05 |